人参皂甙Rh2联合同步放化疗治疗中晚期宫颈癌的临床观察

目的探讨人参皂甙Rh2联合同步放化疗治疗中晚期宫颈癌的临床效果。方法选取2008年3月～2010年3月我院收治的68例中晚期宫颈癌病例,随机分为研究组(34例)和对照组(34例),研究组采用人参皂甙Rh2联合同步放化疗方案治疗,对照组仅采用同步放化疗方案治疗。治疗结束后,观察和比较两组的近期疗效、远期疗效及不良反应。结果研究组和对照组的近期治疗总有效率分别为97.06%和94.12%,差异无统计学意义(P>0.05);研究组的3年生存率(73.53%)、局部复发率(5.88%)和远处转移率(2.94%)与对照组相比(分别为61.76%、8.82%和8.82%),差异均无统计学意义(P>0.05);研究组的胃肠道反应和骨髓抑制的发生率显著低于对照组(P<0.05)。结论人参皂甙Rh2联合同步放化疗治疗中晚期宫颈癌疗效与单纯同步放化疗方案相当,但胃肠道反应和骨髓抑制等不良反应的发生率更低。

---------------

Objective To explore the therapeutic effects of ginsenoside Rh2 plus concurrent chemoradiotherapy on advanced cervical cancer and its adverse reactions. Methods Sixty-eight cases of advanced cervical cancer admitted in our hospital between March, 2008 and March, 2010 were selected and randomly divided into the research group with 34 cases and control group with 34 cases. Patients in the research group were treated with ginsenoside Rh2 plus concurrent chemoradiotherapy, while patients in the control group were treated only with concurrent chemoradiotherapy. The therapeutic effects and adverse reactions were observed and evaluated after treatment. Results The effective rates of the research group and the control group were respectively 97.06% and 94.12% （P〉0.05）. There was no significant difference in the 3-year survival of the research group （73.53% vs. 61.76%）, local recurrence rate （5.88% vs. 8.82%） and distant metastasis rate （2.94% vs. 8.82%） between the two groups （P〉0.05）. The incidence rates of gastrointestinal reactions and bone marrow suppression of the research group were significantly lower than those of the control group （P〈 0.05）. Conclusion Ginsenoside Rh2 plus concurrent chemoradiotherapy was equally effective in the treatment of advanced cervical cancer compared to concurrent chemoradiotherapy alone, and the former had much lower incidence rates of gastrointestinal reactions and bone marrow suppression.